All News
Don’t Buy Guitars (12.6.2024)
This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.
Read Article
ACR24: Rheumatology Roundup
Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.
Read Article
Standardizing Still’s Disease Research: Global Data Harmonization Needed
A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).
Read Article
ACR 2024 - Day 2 Report
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
Read Article
Tocilizumab Efficacy in Giant Cell Arteritis Phenotypes
A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated.
https://t.co/nwCU3qW4PT https://t.co/uhvFDrW5Zz
Dr. John Cush RheumNow ( View Tweet)
Rheumatic findings in sarcoidosis are found in 10–40% of pts and include bone lesions, acute arthritis, chronic arthritis, axial disease, dactylitis, and sarcoid myopathy, https://t.co/WsfmKUS2n5 https://t.co/3j8OHgw7AS
Dr. John Cush RheumNow ( View Tweet)
FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease .… https://t.co/ErNWlva9Nd https://t.co/gc8cPNs3H1
Dr. John Cush RheumNow ( View Tweet)
EULAR and the Paediatric Rheumatology European Society (PReS) and FDA now view systemic juvenile idiopathic arthritis and adult-onset Still’s disease as a single entity — Still’s disease; based on overlapping tests, clinical manifestations, complications & response to biologics… https://t.co/OHfcFymdPx https://t.co/Wm2ciKbMtY
Dr. John Cush RheumNow ( View Tweet)
Standardizing Still’s Disease Research: Global Data Harmonization Needed
A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).… https://t.co/ugsfRj2fnS https://t.co/UJmNvAMo1c
Dr. John Cush RheumNow ( View Tweet)
COVID Associated Immune Disease
Dr. Len Calabrese reports on a session he participated in discussing if Covid-19 is associated or causal for autoimmune disease. Reporting from #ACR24
https://t.co/vFdlf9XVzf https://t.co/JhpglNVIt7
Links:
Dr. John Cush RheumNow ( View Tweet)
Autoantibody tests are everywhere, but how do we make sense of them? With the proper algorithms, can we go beyond interpretation to predicting autoimmunity before it develops?
Check out my article: Taking the AI out of AutoImmunity
https://t.co/d3ZNYWQaaQ
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Long COVID outcomes in Autoimmune diseases (AID)
Abstract 1897:
- Long COVID symptoms higher among AID pts vs controls
- vaccinated may have protective benefit
@RheumNow #ACR24 https://t.co/2SEcbkxfcU
Links:
Akhil Sood MD AkhilSoodMD ( View Tweet)
A#2530
ANA reactive CD4 cells: elevated B cell help activation in SjD
Unique autoreactive T cell cluster in SSc shows CD4+ TRAIL+ IFN type I - unique to SSc
Leads to decrease activation of APCs, decrease CD4 T effector fxn
@RheumNow #ACR24 https://t.co/4JnA3SpVM8
Eric Dein ericdeinmd ( View Tweet)
A#2531 @AlisaMueller
CRISPR deletion of fibroblasts, gave cytokine activation to mimic inflamm
Are there gene depletions that affect inflamm pathways?
👉SIX1 reduces inflamm potentiation
👉NFIL3 deletion promotes inflamm, degradation
@RheumNow #ACR24 https://t.co/Nqghb5UaBR
Links:
Eric Dein ericdeinmd ( View Tweet)
Imaging in TAK Diagnosis
@KQuinnRheum @RheumNow
⭐ Take homes ⭐
👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK
👉FDG PET -focal uptake in TAK vs diffuse in GCA
👉MRI good surrogate for disease activity where PET unavailable
#ACR24 https://t.co/UWxTAZScIt
Links:
Patricia Harkins DrTrishHarkins ( View Tweet)
We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition?
Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt
NO difference in relapse rate at 26, 52 wks despite addition of Anakinra
@RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Comparison of infection risk across b/tsDMARDs in IA in real-world study
Treatment with
➡️Rituximab
➡️JAKi
➡️Anti-IL6
assoc with ⬆️⬆️ risk of severe infection compared to TNFi
A reminder to consider comorbidities & infection risk in selecting b/tsDMARDs
Ab1716 #ACR24 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Is #IL1 inhibition for 4 months a winner in #GCA —NOPE
Anakinra daily 100mg sc 4/12
Underpowered but equal relapses and d/c #steroids not different
#relapses esp after d/c #anakinra
N=30 d/c due to #COVIDpandemic
#1699 #ACR24 @RheumNow @ACRheum https://t.co/1TgloS5x8O
Janet Pope Janetbirdope ( View Tweet)
de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX
Richard Conway RichardPAConway ( View Tweet)
#1165
📊 PBMCs of IIM patients with myocarditis(n=4) showed distinct gene expression v controls(n=4) v IIM alone(n=4)👇
💥 B-cell dysregulation may drive myocarditis in IIM
🎯Key immunological insights into🫀involvement in IIM
#ACR24 @RheumNow @JuliePaikMD @jhrheumatology https://t.co/PceZUS929S
Links:
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
